Treatment of Wegener's granulomatosis;Terapia della granulomatosi di Wegener

Reumatismo

Volumn 56, Issue 2, 2004, Pages 69-76

  Riccieri, Valeria ^a   Valesini, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

DIALYSIS; DRUG MEGADOSE; HUMAN; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; PLASMAPHERESIS; PREGNANCY; PROPHYLAXIS; RELAPSE; REMISSION; REVIEW; SURVIVAL TIME; WEGENER GRANULOMATOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY TRANSPLANTATION; MALE; METHOTREXATE; PLASMAPHERESIS; PREDNISONE; PREGNANCY; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WEGENER GRANULOMATOSIS;

EID: 3142688939     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Hoffman GS. Wegener's granulomatosis. Curr Opin Rheumatol 1993; 5: 11-7.
2. Langford CA. Wegener's granulomatosis: current and upcoming therapies. Arthritis Res Ther 2003; 5: 180-91.
3. De Groot K, Gross WL. Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus 1998; 7: 285-91.
4. Kallenberg CGM. Treatment of Wegener's granulomatosis: new horizons? Clin Exp Rheumatol 1996; 14: 1-4.
5. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Int Med 1983; 98: 76-85.
6. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener's granulomatosis. An analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
7. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101: 129-34.
8. Jayne DR, Rasmussen N, Andrassy K, Bacon P. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
9. DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim-sulfamethoxazole: illusion or vision? Arthritis Rheum 1988; 31: 1068-72.
10. Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988; 148: 2293-5.
11. Leavitt RY, Hoffman GS, Fauci AS. Response: the role of trimethaprim/sulfamethoxazole in the treatment of Wegener's granulomatosis. Arthritis Rheum 1988; 31: 1073-4.
12. De Groot K, Adu D, Savage CO (European vasculitis study group, EUVAS). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Trasplant 2001; 16: 2018-27.
13. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. French Vasculitis Study Group. Arthritis Rheum 2001; 44: 666-75.
14. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective multicenter randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
15. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 6112-18.
16. Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis North Am 1997; 23: 841-53.
17. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
18. De Groot K, Rasmussen N, Bacon PA. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in « non-renal » ANCA-associated vasculitis. Arthritis Rheum 2003; 48: (9) Suppl. 1726.
19. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis. Arthritis Rheum 1999; 42: 2666-73.
20. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange. Blood Purif 2002; 20: 167-73.
21. Kaplan AA. The use of apheresis in immune renal disorders. Therap Apheresis Dial 2003; 7: 165-72.
22. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Arthritis Rheum 1996; 39: 2052-61.
23. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463-9.
24. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM. Prevention of relapses of Wegener's granulomatosis by treatment with trimethaprim/ sulfamethoxazole. A multicenter placebo controlled trial in 81 patients. New Engl J Med 1996; 335: 16-20.
25. Riccieri V, Spadaro A, Parisi G, Benfari G, Trasimeni G, Taccari E, et al. Imaging evidence of successfull multiple immunosuppressive treatment of cerebral involvement in Wegener's Granulomatosis. Clin Exp Rheum 2002; 20: 578-9.
26. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1995; 101: 2-7.
27. Langford CA. Treatment of ANCA-associated vasculitis. N Engl J Med 2003; 349: 3-4.
28. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003; 30: 80-8.
29. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
30. Mekhail TM, Hoffman GS. Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000; 27: 1237-40.
31. Haubitz M, De Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002; 57: 421-4.
32. Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003; 18: 1001-4.
33. Hoffman GS, Thomas-Golbanov CK, Chan J, Akst LM, Eliachar I. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003; 30: 1017-21.
34. Langford CA, Kerr GS. Pregnancy in vasculitis. Curr Opin Rheumatol 2002; 14: 36-41.
35. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenence of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004; 43: 315-20.
36. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of anti-TNFα antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41: 1126-32.
37. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-ot blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-7.
38. Rozin A. Infliximab efficiency in refractory Wegener's granulomatosis. Rheumatology 2003; 42: 1124-25.
39. WEGT Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23: 450-68.